![Mitchell Brigell](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Mitchell Brigell
Directeur Technique/Scientifique/R&D chez OCUPHIRE PHARMA, INC.
Postes actifs de Mitchell Brigell
Sociétés | Poste | Début | Fin |
---|---|---|---|
OCUPHIRE PHARMA, INC. | Directeur Technique/Scientifique/R&D | - | - |
Aerpio Therapeutics, Inc.
![]() Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | Directeur Technique/Scientifique/R&D | - | - |
Corporate Officer/Principal | - | - |
Historique de carrière de Mitchell Brigell
Anciens postes connus de Mitchell Brigell
Sociétés | Poste | Début | Fin |
---|---|---|---|
AERPIO PHARMACEUTICALS | Directeur Technique/Scientifique/R&D | 01/01/2013 | 01/01/2019 |
Novartis Institutes of Biomedical Research
![]() Novartis Institutes of Biomedical Research BiotechnologyHealth Technology Novartis Institutes of Biomedical Research operates a pharmaceutical research organization. The private company is based in Emeryville. | Corporate Officer/Principal | 01/01/2007 | 01/08/2013 |
ISCEV | Corporate Officer/Principal | - | - |
Formation de Mitchell Brigell
Kansas State University | Doctorate Degree |
Statistiques
Internationale
Etats-Unis | 6 |
Allemagne | 2 |
Opérationnelle
Chief Tech/Sci/R&D Officer | 3 |
Corporate Officer/Principal | 3 |
Doctorate Degree | 1 |
Sectorielle
Health Technology | 5 |
Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
OCUPHIRE PHARMA, INC. | Health Technology |
Entreprise privées | 4 |
---|---|
Aerpio Therapeutics, Inc.
![]() Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | Health Technology |
Aerpio Pharmaceuticals, Inc.
![]() Aerpio Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Pharmaceuticals Inc. is a biopharmaceutical company, which engages in the research and development of treatments for ocular diseases. The firm's product candidate is AKB-9778, a small molecule activator of the Tie2 pathway, which completed the Phase 2a clinical trial for the treatment of diabetic retinopathy. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications; and AKB-4924, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed a single ascending dose clinical trial for the treatment of inflammatory bowel disease. The company was founded by Joseph H. Garder on November 16, 2007 and is headquartered in Cincinnati, OH. | Health Technology |
Novartis Institutes of Biomedical Research
![]() Novartis Institutes of Biomedical Research BiotechnologyHealth Technology Novartis Institutes of Biomedical Research operates a pharmaceutical research organization. The private company is based in Emeryville. | Health Technology |
ISCEV |
- Bourse
- Insiders
- Mitchell Brigell
- Expérience